Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
This is a structured narrative review synthesizing evidence and international guidelines on surgical management of borderline resectable pancreatic cancer in the neoadjuvant therapy era, offering a practical decision-making framework rather than reporting original trial data.
Single case report with no control group, describing tolerance of anti-PD-1 therapy in an unusual patient population; raises a question about feasibility rather than establishing efficacy or safety.
Single-center prospective observational study with modest sample size (n=31) and surrogate endpoint (ORR at 3 months); demonstrates feasibility in a LMIC setting but lacks a comparator and control group, and requires confirmation in larger studies.
A modeled cost-effectiveness analysis from a single healthcare system showing the intervention meets the threshold, but dependent on assumptions about treatment duration and subsequent costs that proved sensitive in scenario testing.
Early-stage in vitro study using patient-derived cell models without clinical outcomes, animal efficacy data, or in vivo validation; demonstrates proof-of-concept for a combination strategy but requires substantial further development before clinical relevance can be assessed.
Retrospective case series of 12 patients with no concurrent control group, reporting observational outcomes of local therapy after ICI; suggestive but uncontrolled, and too small to guide practice change.
A narrative review synthesizing molecular mechanisms and treatment strategies in RCC, offering expert perspective on current and emerging approaches rather than reporting original research findings.
Retrospective integration of longitudinal biomarkers, dual-modal imaging, and genomics in a single-centre cohort identifies genotype-phenotype associations in RAIR-DTC, but lacks prospective validation or a randomized comparator to establish clinical utility.